Curity Pharma, a new and rapidly emerging Greek pharmaceutical company, announces the signing of a strategic partnership with Galenica S.A., one of the most reputable and established providers of pharmaceutical products and services in Greece. The partnership concerns the commercial distribution and marketing of Curity Pharma’s medical cannabis products in the Greek market.
At Impactus ESG, we are proud to support the strategic partnership between Curity Pharma S.A. and Galenica S.A., a milestone collaboration that brings high-quality medical cannabis products to patients across Greece.
Curity Pharma enters the medical cannabis sector with a diversified portfolio of eight products, designed to allow physicians to select the appropriate formulation for each patient, based on their immediate and long-term needs. The company aims to offer modern products based on scientific evidence, quality, and safety.
Galenica, with its many years of experience and expertise in the development, import, distribution, and support of innovative pharmaceutical products, shares Curity Pharma’s vision for the modern era of medical cannabis and contributes significantly to the initiative by leveraging its extensive network, scientific knowledge, and commercial strength.
Mr. Manos Chatiras, Co-founder, President and CEO of Curity Pharma, stated:
“At Curity Pharma, we believe in scientifically substantiated and personalized medical care for every individual. Our collaboration with Galenica—a pharmaceutical company with a long-standing reputation and credibility in the industry—lays the foundation for our market entry, with the goal of meaningfully improving patients’ quality of life through the responsible use of medical cannabis.”
Mr. Nikolaos Varelas, Chairman of the Board and CEO of Galenica S.A., stated:
“As a purely Greek pharmaceutical company with over 50 years of contribution to health, Galenica remains committed to innovation and ensuring patients’ access to treatments that address today’s medical needs.
Medical cannabis is internationally recognized as a significant therapeutic option for specific conditions, and its responsible use aligns with our vision of comprehensive, patient-centered healthcare.
Our strategic partnership with Curity—an ambitious Greek company—reaffirms our commitment to supporting Greek production and entrepreneurship, investing in therapeutic solutions that provide added value to both patients and the national economy.”
About Curity Pharma
Curity Pharma’s facility spans a privately-owned area of 67,000 sq.m. in the Industrial Zone of Larissa. Its infrastructure includes a state-of-the-art 5,000 sq.m. hybrid greenhouse unit for the cultivation of medical cannabis, as well as a 1,800 sq.m. production facility operating according to Good Manufacturing Practice (GMP) standards.
Curity Pharma remains committed to delivering safe and effective therapeutic solutions, while reinforcing Greece’s position as a significant hub in the European pharmaceutical industry.
